Ascletis
Specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| CNY | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (80 %) | 120 % | (30 %) | 5 % | (98 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (8 %) | (369 %) | (216 %) | (430 %) | (345 %) | (21193 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (55 %) | (598 %) | (259 %) | (582 %) | (256 %) | (23456 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 73 % | 312 % | 277 % | 494 % | 383 % | 23569 % |
Source: Company filings or news article
Related Content
Ascletis Pharma Inc. is a fully integrated antiviral platform focused on developing and commercializing innovative, best-in-class drugs against Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Hepatitis B Virus (HBV). The company operates in the biopharmaceutical sector, serving both domestic and global markets. Ascletis targets healthcare providers and patients in need of advanced antiviral treatments. The business model revolves around the entire value chain from drug discovery and development to manufacturing and commercialization. Revenue is generated through the sale of its antiviral drugs, which offer high cure rates and shorter treatment periods.
The company boasts a management team with deep expertise and a proven track record, and it emphasizes a positive work environment that encourages courageous innovation. Ascletis is also committed to eliminating viral hepatitis as a major public health threat by 2030.
Keywords: antiviral drugs, HCV, HIV, HBV, biopharmaceutical, drug discovery, commercialization, healthcare, innovation, high cure rates.
Tech stack
Investments by Ascletis
Edit